You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,280,465

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,280,465

Title:	Biomarkers for predicting relapse in multiple sclerosis
Abstract:	Methods of determining relapse in subjects having relapsing-remitting multiple sclerosis (RRMS) and predicting their response to glatiramer acetate (GA) using the biomarkers SIRT1, RGC-32, FasL and IL-21 are presented.
Inventor(s):	Rus; Horea G. (Catonsville, MD), Tegla; Cosmin A. (Bronx, NY)
Assignee:	UNIVERSITY OF MARYLAND, BALTIMORE (Baltmore, MD) THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (Washington, DC)
Application Number:	14/978,772
Patent Claims:	1. A method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse of the disease, comprising: (a) determining mRNA expression levels for one or more of biomarkers SIRT1 and RGC-32 in a population of cells isolated from a subject having RRMS, (b) determining the mRNA expression level for L13 in the same population of cells, (c) selecting SIRT1 as the biomarker and calculating a SIRT1/L13 ratio of <3.06+/-10%, or selecting RGC-32 as the biomarker and calculating a RGC-32/L13 ratio of <1.27+/-10%, (d) diagnosing the subject in (c) as undergoing relapse, and (e) administering a therapeutically effective amount of a treatment for RRMS to the subject diagnosed in (d). 2. The method of claim 1 comprising selecting SIRT1 as the biomarker and calculating a SIRT1/L13 ratio of <3.06+/-10%. 3. The method of claim 1 comprising selecting RGC-32 as the biomarker and calculating a RGC-32/L13 ratio of <1.27+/-10%. 4. The method of claim 1, wherein mRNA expression levels for both biomarkers are determined. 5. The method of claim 1, wherein the treatment is selected from the group consisting of glatiramer acetate (GA), beta-interferons, teriflunomide, fingolimod, dimethyl fumarate, and natalizumab. 6. The method of claim 1, wherein the population of cells is selected from the group consisting of peripheral blood mononuclear cells (PBMCs), CD4+ T cells, CD8+ T cells, MAB328+ cells, GFAP+ cells, leukocytes, monocytes, glial cells, dendritic cells, and neurons. 7. The method of claim 1, wherein the treatment is glatiramer acetate (GA). 8. The method of claim 1, wherein the population of cells is peripheral blood mononuclear cells (PBMCs).

Details for Patent 10,280,465

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004	⤷ Try a Trial	2039-05-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.